Article Information
History
- November 29, 2022.
Article Versions
- Version 1 (September 19, 2022 - 19:44).
- Version 2 (September 20, 2022 - 12:38).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Rocky Lai1,
- Diana Gong2,
- Travis Williams1,
- Abiola F. Ogunsola1,
- Kelly Cavallo1,
- Cecilia S. Lindestam Arlehamn3,
- Sarah Acolatse2,
- Gillian L. Beamer4,
- Martin T. Ferris5,
- Christopher M. Sassetti1,
- Douglas A. Lauffenburger2 and
- Samuel M. Behar1,*
- 1Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA
- 2Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
- 3Center for infectious disease and vaccine research, La Jolla Institute for Immunology., La Jolla, CA, USA
- 4Texas Biomedical Research Institute, San Antonio, TX, USA
- 5Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, United States
- ↵*Correspondence: Samuel M. Behar, E-mail address: samuel.behar{at}umassmed.edu
Posted November 29, 2022.
Host genetic background is a barrier to broadly effective vaccine protection: Relevance to BCG and Mycobacterium tuberculosis Infection
